Agenus Announces Peer-Reviewed Publication Linking BOT+BAL’s Durable Survival in MSS Metastatic Colorectal Cancer to Its Distinct Immune-Priming Mechanism
Go back to Agenus Announces Peer-Reviewed Publication Linking BOT+BAL’s Durable Survival in MSS Metastatic Colorectal Cancer to Its Distinct Immune-Priming Mechanism| AGENUS (NASDAQ: AGEN) | Delayed: 7.85 +0.63 (8.73%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $7.22 | 52 Week High | $7.49 | |||
| Open | $7.48 | 52 Week Low | $2.61 | |||
| Day High | $7.88 | P/E | N/A | |||
| Day Low | $7.33 | EPS | $-1.10 | |||
| Volume | 2,084,681 | |||||
